Liang C M, Herren S, Fountoulakis M, Otto B, Hirschi M, Gutzwiller E, Gerlis L
Clin Immunol Immunopathol. 1985 Jul;36(1):95-100. doi: 10.1016/0090-1229(85)90042-x.
Recombinant Escherichia coli-derived human interferon-gamma (rIFN-gamma) was given to a total of 20 patients by iv bolus injection at various doses once a week for 4 weeks. The sera obtained 7-10 days after the final injection were analyzed for antibodies against both rIFN-gamma and natural human IFN-gamma. Biological assays demonstrated that the postinoculation sera of the patients did not neutralize the antiviral activities of either rIFN-gamma or natural human IFN-gamma. Enzyme-linked immunosorbent assay showed that no detectable antibodies against rIFN-gamma were elicited. These results indicate that this rIFN-gamma preparation is not a potent antigen and may be suitable for longer-term clinical trials and applications in the future.
将重组大肠杆菌衍生的人干扰素-γ（rIFN-γ）以不同剂量通过静脉推注的方式给予20名患者，每周一次，共4周。在最后一次注射后7至10天采集的血清进行分析，检测针对rIFN-γ和天然人干扰素-γ的抗体。生物学检测表明，患者接种后的血清未中和rIFN-γ或天然人干扰素-γ的抗病毒活性。酶联免疫吸附测定显示未引发可检测到的针对rIFN-γ的抗体。这些结果表明，这种rIFN-γ制剂不是一种强抗原，未来可能适用于长期临床试验和应用。
